Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactoferrin + immunoglobulin
- Development stage
- Unknown
- Lead developer
- Probiotec Pharma
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Lactoferrin + Immunoglobulin (Glycomax™) is an oral biologic/nutraceutical combination developed by Probiotec Pharma for the prevention and treatment of the common cold. It consists of bovine lactoferrin and a bovine whey-derived immunoglobulin-rich fraction. Lactoferrin is a multifunctional glycoprotein that inhibits viral entry by binding to viral surface proteins or host cell receptors (such as heparan sulfate proteoglycans), while the immunoglobulins provide passive immunity by binding directly to respiratory pathogens like rhinovirus, RSV, and influenza. The product has been evaluated in a Phase IIa clinical trial in Australia to assess its efficacy in reducing the incidence and duration of upper respiratory tract infection symptoms.
- Brand names
- Glycomax
- Other names
- lactoferrin/immunoglobulin preparation
02
Targets
HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))LRP1 (Prolow-density lipoprotein receptor-related protein 1)HA (Hemagglutinin)
Beyond the preview
Go deeper on lactoferrin + immunoglobulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactoferrin + immunoglobulin.